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Physicians  usually  do  not  suspect  pulmonary  thromboembolism  in 
younger  patients  except  in  those  who  have  thrombophilia.  In  those  latter 
patients some special conditions such as trauma or surgery may provoke the 
disease. In some adult persons, thrombophilia may still remain unrecognized, 
until appearance of additional conditions influence development of thrombosis.   
A 55-year-old Caucasian female, non- smoker, experienced sudden chest pain 
and hemoptysis without chest trauma.  History taking revealed type 2 diabetes 
mellitus and hypothyroidism. She was overweight with body mass index 29.0.  
The review of the family history revealed that her father and mother died of 
brain  infarction,  while  her  22-year-old  son  and  24-year-old  daughter  were 
healthy. Due to suspicion for thrombosis, multi-slice computerized tomography 
thorax  scan  was  done  and  pulmonary  embolism  was  diagnosed.  Although 
without clear risk factor for thrombosis in our patient, we performed laboratory 
investigation for congenital thrombophilia.  Genetic analysis showed double 
heterozygous  for  factor  V  Leiden  and  prothrombin  20210  G>A  mutations. 
Congenital  thrombophilia  was  risk  factor  for  thrombosis  in  our  patient  but 
haemostatic imbalance was not previously clinically recognized. She had two 
pregnancies without complications.  Appearance of other associative factors 
such as endocrine disorders - hypothyroidism and metabolic syndrome with 
diabetes type 2, and overweigh were additional potential triggers for clinical 
manifestation of pulmonary thromboembolism in her adult age. Her children 622                                                                                                             GENETIKA, Vol. 46, No.2,621-629, 2014 
underwent  genetic analysis, too. The son was also  double heterozygous for 
factor V Leiden and prothrombin 20210 G>A mutations, while daughter was 
heterozygous for factor V Leiden, and none had clinical signs of thrombosis
   Key words: pulmonary thromboembolism, thrombophilia, risk factors, 
genetic.               
 
INTRODUCTION 
Thrombophilia is defined as an increased tendency to develop thrombosis, which is 
familial,  recurrent,  and  present  at  unusual  site  or  manifested  in  young  age.  Typical  clinical 
manifestation  of  thrombophilia  is  venous  thromboembolism  (VTE),  including  deep  venous 
thrombosis (DVT) and pulmonary thromboembolism (PTE). Thrombophilia is a good model of 
polygenic trait with clearly associated genetic risk factors.  
Resistance to activated protein C (APC) is the most common inherited hypercoagulable 
state found to  be associated with venous thrombosis (ROSENDAAL and  REITSMA, 2009). It is 
caused by a single point mutation in the factor V gene known as factor V Leiden (FVL). FVL 
mutation  (1691  G>A)  predicts  the  substitution  of  arginine  (Arg)  with  a  glutamine  (Gln)  at 
position 506. Arg 506 is one of three APC- cleavage sites and the mutation results in the loss of 
this site; as a consequence coagulation cascade continues unchecked. FVL is a common unique 
gain-of-function mutation, with a prevalence of carriers among Caucasians of approximately 5%. 
Among  patients  with  venous  thrombosis  it  is  found  in  20%,  and  in  approximately  50%  of 
patients with familial thrombophilia. The risk of thrombosis is 5-fold increased in heterozygotes, 
and fiftyfold in homozygotes (ROSENDAAL and REITSMA, 2009). 
The substitution guanine to adenine (G>A) in prothrombin gene at position 20210 is the 
second most common inherited risk factor for VTE (ONER et al., 2003; MARGETIĆ, 2014).  It is a 
variant located in the 3' untranslated region (UTR) of gene, supposed to have a regulatory role. 
Mutation predisposes humans towards forming blood clots in the veins and it confers an about 2- 
to  3-fold  higher  risk  of  thrombosis  (ROSENDAAL  and  REITSMA,  2009).    About  2  to  3%  of 
Caucasians carry the variant, and it is present in about 6% of all individuals that have venous 
thrombosis  (ROSENDAAL,  2005). The carriers  of  two  mutations  in  factor  V  and  prothrombin 
genes (homozygous or double heterozygous) have as much as 20 times higher risk (ROSENDAAL 
and REITSMA, 2009). 
We  here  report  on  a  55-year-old  female  with  previously  unrecognized  congenital 
thrombophilia until additional triggers for coagulation abnormalities have been associated. The 
publication of the case is approved by the Ethical committee of the Clinical Center of Serbia in 
Belgrade (14/4-2014). 
 
CASE REPORT 
A 55-year-old female, non-smoker, has been hospitalized for sudden strong thoracal 
pain and hemoptisis. From personal history: she takes oral therapy for diabetes type 2, as well as 
hormonal substitution therapy for hypothireosis. She had two pregnancies without complications 
and had no miscarriages. Body mass index (BMI) was 29.0. She denies any previous injuries or 
thrombosis. The review of the family history revealed that her father and mother died of brain 
infarction.  
She was febrile (37,5ºC), cardially compensated, with heart rate 70 beats min
-1, blood 
pressure  120/80  mmHg  and  respiratory  rate  18  breaths  min
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examination was normal. Electrocardiogram, routine laboratory findings and arterial blood-gas 
analysis gave normal results. Blood sedimentation rate was 70 mm h
-1, C reactive protein was 
21mg/L (reference range 0-8 mg/L), and   specific degradation products of cross-linked fibrin 
(D-dimer) was 4.3mg/L (reference  range 0-0.55 mg/L). Antinuclear antibodies, antineutrophil 
cytoplasmic antibodies, and antiphospholipid antibodies were not present such as serum tumor 
markers. 
Clinical prediction for PTE ussing revised Geneva score showed low possibility (LE 
GAL  et  al.,  2006).  Color  duplex  scan  of  the  veins  on  both  extremities  showed  no  signs  of 
thrombosis  of  deep  and  superficial  veins.  But,  as  she  had  family  history  for  thrombosis, 
multislice computed tomography (MSCT) of the lung was performed and it showed thrombosis 
of  lower  lobar  branch  of  the  right  pulmonary  artery  (Fig.1,2)  and  occasional  thrombosis  of 
segmental branches for upper right and left lobus. In right lower lobe posteriorly and lateraly, 
subpleural a focal iregular opacities were showed (Fig.2). There were no signs of effusion in 
pleural, pericardial, intra and retroperitoneal spaces.  
 
 
 
 
 
Figure 1. Axial thoracic CT scan in mediastinal window shows thrombosis of lower lobar branch of the 
right pulmonary artery (arrow) 
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Figure 2. Coronal thoracic CT scan in mediastinal window shows thrombosis of lower lobar branch of the 
right pulmonary artery (arrow) and subpleural irregular opacitis in right lower lobe (arrowhead). 
 
 
Therapy  started  with  intravenous  heparin,  followed  by  warfarin,  keeping  the 
international rate (INR) of prothrombin time at 2-3 range. The patient's clinical state has been 
gradually improved and over 2 years of follow-up she had no new thrombotic episodes. 
Concering the fact that her parents had brain infarctions, additional genetic examination 
of hypercoagulable state was done and findings showed that the patient was double heterozygous 
for  FVL and prothrombin 20210G>A mutations. Methylene-tetrahydrofolate-reductase genotype  
(MTHFR 677 C>T) was wild type homozygous. Analyzes were also performed in her children 
who had no clinical signs of thrombosis.  Her 24-year-old daughter, was heterozygous for FVL 
mutation,  and  her  22-year-old  son,  was  double  heterozygous  for  FVL  and  prothrombin 
20210G>A  mutations. 
Genetic methodology description 
Genomic DNA for molecular genetic analyzes was extracted from 5ml of peripheral 
blood  by  salting  –  out  method.  Detection  of  factor  V  Leiden  and  prothrombin  20210  G>A 
mutations was done using polymerase chain reaction/ restriction fragments length polymorphism 
(PCR/RFLPs)  method:  amplification  of  the  selected  gene  region  by  PCR  is  followed  with 
digestion  of  PCR  products  with  corresponding  restriction  endonuclease  enzyme  in  order  to 
observe RFLPs connected to the mutation. For detection of factor V Leiden and prothrombin LJ.NAGOMI OBRADOVIC et al:   PHENOTYPIC PRESENTATION OF THROMBOPHILIA                               625 
20210 G>A mutations restriction endonucleases MnlI and HindIII were used, respectively, and 
PCR/RFLPs protocols were as described previously (BERTINA, 1994; POORT, 1996; PECHENIUK, 
2000). After electrophoresis of restriction fragments on 8% polyacrylamide (PAA) gel genotypes 
were detected according to the observed patterns.  
DISCUSSION 
PTE is one of the most common undiagnosed conditions affecting hospitalized patients 
(SOO  HOO,  2013).  Diagnostic  procedure  can  be  challenging  with  a  diverse  range  of  clinical 
presentations  from  asymptomatic  to  death.  Various  resources  are  available,  such  as  clinical 
scoring systems, laboratory data, and imaging studies which help guide clinicians in their work-
up of PTE. Prompt recognition and treatment are essential for minimizing the mortality and 
morbidity associated with PTE (TARBOX and SWAROOP, 2013). DVT and PTE are distinct but 
related aspects of the same dynamic disease process known as VTE. However, clinical history 
and examination can be notoriously misleading in reaching a diagnosis. A number of acquired 
etiologic risk factors  are associated with a tendency to develop VTE. These include increasing 
age,  immobilization,  surgery,  trauma,  including  invasive  diagnostic  procedures  (NAGORNI-
OBRADOVIĆ et al., 2009; PEŠUT et al., 2011), hospital or nursing home confinement, malignancy, 
neurologic disease with extremity paresis, as well as certain types of oral contraception and 
hormone replacement therapy. In addition, a variety of genetic risk factors, such as FVL and 
prothrombin  mutations,  protein  S  or  C  deficiency  have  also  been  identified  (NAGORNI-
OBRADOVIĆ et al., 1997). 
Genetic  testing  in  thrombophilia  is  a  good  example  of  the  power,  specificity  and 
sensitivity of molecular genetic testing in disease management (NOVAKOVIĆ et al., 2014).  A 
positive family history is an independent risk factor for VTE that may reflect the presence of a 
hereditary thrombophilic disorder. However, the predictive value of a positive family history for 
detection of known heritable causes of VTE is low, suggesting that there are as-yet undiscovered 
genetic or environmental risk factors that account for the familial clustering of this disorder 
(TARBOX and SWAROOP, 2013 ; EIKELBOOM and WEITZ, 2011;  BEZEMER , 2009). 
  Presented  female  Caucasian,  did  not  have  clear  risk  factors  for  thrombosis  such  as 
posttraumatic state, recent immobilization or others. She could be misdiagnosed for PTE but she 
had positive family history for thrombosis, and it was a reason for doing laboratory investigation 
for thrombophilia. Today, thrombophilia testing is most commonly performed in young patients 
with VTE, patients with recurrent episodes of VTE or with thrombosis at unusual sites and in 
persons with positive family history (MITIĆ, 2014). Molecular genetic testing is today part of 
modern medical practice. In our patient genetic analysis showed double heterozygous for FVL 
and 20210G>A, a mutation in prothrombin. Positive family history for VTE in a first-degree 
relative increases the risk for VTE occurrence by 2-fold, regardless of the presence of inherited 
thrombophilia (MITIĆ, 2014). Patients in whom thrombophilia testing  is still  debated include 
those with unprovoked VTE over 50 years of age. Although age over 50 years is considered to 
be exclusion risk factor for testing, it is described that relatively weak hereditary risk factors 
such as heterozygosity for FVL  and prothrombin 20210G>A mutations  may results in a first 
VTE also in subjects older than 50 years (MITIĆ, 2014; DE STEFANO, 2003). On the other hand, 
testing of the patients aged 50 years or more might be important from clinicians point of view in 
terms of therapy duration (PEŠUT et al., 2011). Family history is a potentially useful genetic 626                                                                                                             GENETIKA, Vol. 46, No.2,621-629, 2014 
surrogate marker for clinical VTE risk assessment, even in second- and third degree-relatives 
(ZÖLLER, 2013).  
One of the laboratory useful markers for PTE is plasma D-dimer level (KLINE, 2008; 
GOLDHABER and BOUNAMEAUX, 2012) which is usually elevated as in our patient. But normal 
plasma  D-dimer  level  do  not  exclude  PTE  such  as  described  in  patient  with  atypical  chest 
bilateral nodular infiltrates and prothrombin 20210G>A mutation(NAGORNI-OBRADOVIĆ et al., 
2009). 
Why has not our patient developed PTE at younger age? Although VTE at a young age 
is an important feature of thrombophilia, the first thrombotic episode may happen later in life 
(MARGETIĆ, 2014). Some persons with thrombophilia do not experience a thrombotic event if 
additional triggering transient risk factors are not present. Interactions between hereditary or 
acquired thrombophilic defects and transient risk factors further increase the risk of VTE as a 
result of their synergistic interactions (NAGORNI-OBRADOVIĆ et al., 2000). In presented person 
with  previously  unknown  hereditary  risk  for  thrombosis,  additional  triggers  appeared  and 
influenced  her  coagulation  state.  Patients  with  clinically  hypothyroidism  appear  to  have  an 
increased risk of bleeding, whereas those with hyperthyroidism are more likely to be prone to 
thrombosis. At present, very little information is still available on haemostatic abnormalities in 
patients with subclinical hypo- or hyperthyroidism (FRANCHINI et al., 2010; SQUIZZATO et al., 
2007; FRANCHINI et al., 2009). Future clinical trials on larger series of patients are undoubtedly 
required to better clarify the haemostatic abnormalities in patients with thyroid dysfunctions. It is 
suggested  that  the  influence  of  thyroid  dysfunction  on  coagulation  and  fibrinolysis  mainly 
depends on the type of thyroid disorder. 
As  our  patient  had  diabetes  mellitus  type  2  and  higher  BMI,  there  were  another 
potential risks factors for hypercoagulable state. Metabolic syndrome is frequently associated 
with  a  hypercoagulable  condition,  in  that  the  coagulation  system  is  switched  toward  a 
prothrombotic state, involving increased plasmatic coagulation, reduced fibrinolysis, decreased 
endothelial thromboresistance, and predominantly platelet hyperactivity (FRANCHINI et al., 2010; 
CORNIER et al., 2008). For a long time, obesity has been regarded as a risk factor for VTE 
(BRAEKKAN et al., 2013). The risk positively correlates with BMI.  
After  the  age  of  50,  the  other  factors  for  VTE  appear  to  play  a  greater  role  than 
hereditariness. Epidemiologic studies showed that the highest risk occurs if both parents had 
clinical manifestation of VTE. For that reason family history of VTE is an important risk factor 
for  thrombosis  and  this  data  should  be  included  in  the  clinical  medical  history  and  further 
examinations for thrombophilia (SOO HOO, 2013 ; EIKELBOOM and WEITZ, 2011; ZÖLLER, 2013;  
PEŠUT et al., 2014). 
Although  her  children  did  not  have  clinical  findings  of  thrombosis,  we  conducted 
genetic testing for thrombophilia in them. The results showed heterozygous for FVL mutation in 
daughter and son was double heterozygous for prothrombin 20210 G>A mutation and FVL. 
Like their mother, children may not develop thrombosis at their young age, but it can be 
useful for them to know data about hemostasis abnormalities. Trauma and surgery can provoke 
thrombotic event in both daughter and son with defined hereditary thrombophilia, but the risk 
might be higher in son who carries two mutations.  In addition, physicians should pay attention 
on women in fertile age with positive thrombosis family history and presence of thrombophilia. 
The  condition  may  benefit  from  thromboprophylaxis  implementation  during  pregnancy.  The LJ.NAGOMI OBRADOVIC et al:   PHENOTYPIC PRESENTATION OF THROMBOPHILIA                               627 
women should be advised not to use oral contraceptives to prevent thrombotic event (MARGETIĆ, 
2014; MITIĆ, 2014). 
CONCLUSION 
Thrombophilia testing should be considered in patients with family history of VTE. Presented 
patient with hypothyroidism, diabetes mellitus type 2 and overweight had transient risk factors 
which may influence haemostatic abnormalities and PTE in previously undetected thrombophilia 
with double heterozygous for FVL and prothrombin 20210G>A mutations. Physicians should 
consider potential associated factors for thrombosis much more, which in one moment could be 
the triggers for clinical manifestation of PTE in adults due to congenital    
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Izvod 
Lekari obično ne  posumnjaju na plućnu tromboemboliju kod mladjih bolesnika osim kod onih 
koji  imaju trombofiliju. Kod takvih bolesnika neki posebni uslovi kao što su trauma ili operacija 
mogu da provociraju pojavu bolesti. Kod nekih odraslih osoba,trombofilija može još uvek da 
ostene neprepoznata, sve do pojave pridodatih uslova koji mogu uticati na razvitak tromboze. 
Bolesnica 55 godina, bele rase, nepušač, iznenada je osetila bol u grudnom košu sa pojavom 
hemoptizija bez prethodne traume. Bolovala je od  tipa 2 šećerne bolesti i od hipotiroidizma. Bila 
je gojazna sa indeksom telesne težine 29. Podaci o oboljevanju u porodici su ukazali da su i otac 
i majka umrli zbog infarkta mozga, dok su 22 godine star sin i 24 godina stara ćerka bili zdravi. 
Zbog sumnje na trombozu, uradjena je multislajzna kompjuterizovana tomografija grudnog koša 
i dijagnostikovana je plućna tromboembolija. Mada opisana bolesnica nije imala jasan faktor 
rizika za trombozu,  učinjeno je laboratorijsko ispitivanje za kongentialnu trombofiliju. Genetske 
analize su pokazale da je ona dvostruki heterozigot za factor V Leiden i protrombin 20210 G>A 
mutacije.  Urodjena  trombofilija  je  bila  factor  rizika  za  trombozu  kod  opisane  bolesnice,  ali 
hemostazni disbalans nije ranije bio klinički prepoznat. Imala je dve trudnoće bez komplikacija. 
Pojava  drugih  pridodatih  faktora  kao  što  su  endokrini  poremećaji  -  hipotiroidizam  i 
metaboličkog sindroma sa šećernom bolesti tipa 2 kao i prisustvo gojaznosti  su bili potencijalni 
okidači za kliničko ispoljavanje plućne tromboembolije u  njenom odraslom životnom dobu. Kod 
njene dece su takodje uradjene genetske analize. Sin je bio takodje dvostruki heterozigot za 
faktor V Leiden i protrombin 20210 G>A mutacije, dok je ćerka bila heterozigot za faktor V 
Leiden mutaciju  a nisu imala kliničke znakove tromobze.  
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